Ivermetcin - No real improvement in outcomes, page-14

https://ivmmeta.com/

Meta analysis using the most serious outcome reported shows 74% and85% improvement forearlytreatment and prophylaxis(RR0.26[0.16-0.43] and0.15[0.08-0.25]), with similar resultsafterexclusion based sensitivity analysis,restriction to peer-reviewed studies,and restriction to Randomized Controlled Trials.

•64% and96% lower mortality is observed for early treatment and prophylaxis(RR 0.36[0.15-0.85] and0.04[0.00-0.59]). Statisticallysignificant improvements are seen formortality,hospitalization,cases,and viral clearance.26studies show statistically significant improvements in isolation.

The probability that an ineffectivetreatment generated results as positive as the60 studies to date is estimated to be 1 in193 billion (p = 0.0000000000052).

Abstract

Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (3328 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv and trial registries. Ivermectin was associated with reduced inflammatory markers (C-Reactive Protein, d-dimer and ferritin) and faster viral clearance by PCR. Viral clearance was treatment dose- and duration-dependent.In 11 randomized trials of moderate/severe infection, there was a 56% reduction in mortality (Relative Risk 0.44 [95%CI 0.25-0.77]; p=0.004; 35/1064 (3%) deaths on ivermectin; 93/1063 (9%) deaths in controls) with favorable clinical recovery and reduced hospitalization

https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab358/6316214

Conclusions: Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally.

https://pubmed.ncbi.nlm.nih.gov/34145166/